厦门国贸(600755)：重视股东回报 静待需求回暖

Core Viewpoint - Xiamen International Trade Group has reported a significant decline in revenue and net profit for 2024, with a focus on improving supply chain management and health technology business performance in 2025 [1][2][3][4]. Financial Performance - In 2024, the company achieved operating revenue of 354.44 billion yuan, a decrease of 24.30% year-on-year, and a net profit attributable to shareholders of 626 million yuan, down 67.33% year-on-year [1]. - The net cash flow from operating activities was -931 million yuan, compared to 3.206 billion yuan in the same period of 2023 [1]. - Basic earnings per share were 0.04 yuan, a decline of 93.75% year-on-year, and the weighted average return on equity was 0.37%, down 6.28 percentage points year-on-year [1]. Quarterly Performance - In Q4 2024, the company reported operating revenue of 68.11 billion yuan, an increase of 0.86% year-on-year but a decrease of 25.25% quarter-on-quarter [1]. - The net profit attributable to shareholders in Q4 was -8.6 million yuan, compared to a profit of 4.9 million yuan in the same period of 2023, although the loss narrowed [1]. - For Q1 2025, the company achieved operating revenue of 70.53 billion yuan, a decrease of 27.19% year-on-year but an increase of 3.56% quarter-on-quarter, with a net profit of 422 million yuan, up 2.76% year-on-year [1]. Supply Chain Management - In 2024, the supply chain management business generated revenue of 353.22 billion yuan, down 24.09% year-on-year, with overseas revenue of 65.86 billion yuan and total import-export volume of 14.418 billion USD [2]. - The overall gross margin for the supply chain management business improved to 1.83%, an increase of 0.36 percentage points year-on-year, despite a decline in operating volume for major categories [2]. - Key product categories such as iron ore, steel, and coal maintained strong market positions, with significant improvements in gross margins [2]. Health Technology Business - The health technology segment reported revenue of 1.103 billion yuan in 2024, a growth of 49.61% year-on-year, with a gross margin of 41.04%, up 16.31 percentage points [3]. - The subsidiary, Paiter Medical, achieved revenue of 584 million yuan, a year-on-year increase of 15.42%, with over 50% of its revenue coming from overseas markets [3]. Shareholder Returns - The company announced a cash dividend of 0.33 yuan per share for 2024, totaling 715 million yuan, which represents 114.32% of the annual net profit attributable to shareholders, with a year-on-year increase in the dividend payout ratio of 56.76 percentage points [4]. - For 2025, the company plans to continue mid-term cash dividends, with amounts not exceeding 50% of the net profit attributable to shareholders for the corresponding period [4]. Profit Forecast and Valuation - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 1.359 billion yuan, 1.657 billion yuan, and 1.976 billion yuan respectively [4]. - The projected earnings per share for 2025-2027 are 0.63 yuan, 0.76 yuan, and 0.91 yuan, with the current stock price at 6.27 yuan, resulting in corresponding price-to-earnings ratios of 10.0X, 8.2X, and 6.9X [4].